Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 10/20 | 0.55 |
| ▸ | GLP1R | P43220 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | GRPR | P30550 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434537 | 0.93 | GLP1R (0.57) | IL23RGLP1RGRPR | |
| SCHEMBL29871710 | 0.93 | CTSL (0.53) | IL23RGLP1RCTSLCTSSCTSK | |
| SCHEMBL30183034 | 0.92 | GLP1R (0.55) | IL23RGLP1RCTSLCTSSCTSK | |
| SCHEMBL29484310 | 0.92 | CTSL (0.53) | IL23RGLP1RCTSLCTSSCTSK | |
| SCHEMBL30064553 | 0.91 | GLP1R (0.58) | IL23RGLP1RGRPR | |
| SCHEMBL30932144 | 0.90 | GLP1R (0.59) | GLP1R | |
| SCHEMBL30496771 | 0.90 | CTSL (0.50) | IL23RGLP1RCTSLCTSSCTSK | |
| SCHEMBL29740501 | 0.89 | GLP1R (0.59) | IL23RGLP1R | |
| SCHEMBL30932143 | 0.88 | GLP1R (0.60) | GLP1R | |
| SCHEMBL29489380 | 0.88 | CTSL (0.53) | IL23RGLP1RCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259187-A1 | GENOMIC EDITING OF COMPLEMENT | Apellis Pharmaceuticals, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125955-A1 | GENOMIC EDITING OF COMPLEMENT | APELLIS PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |